AIMS/HYPOTHESIS: Some previous studies suggested that metformin might attenuate the effects of exercise on glycaemia or fitness. We therefore examined whether metformin use influenced changes in glycaemic control, fitness, body weight or waist circumference resulting from aerobic and/or resistance training in people with type 2 diabetes participating in an exercise intervention trial. METHODS: After a 4 week run-in period, participants from the Diabetes Aerobic and Resistance Exercise (DARE) trial were randomly assigned to 22 weeks of aerobic training alone, resistance training alone, combined aerobic and resistance exercise training or a waiting-list control group. Of the 251 randomised, 143 participants reported using metformin throughout the entire study period and 82 reported not using metformin at all. RESULTS: Compared with control, aerobic training led to a significant reduction in HbA1c in the metformin users (-0.57%, 95% CI -1.05, -0.10; -6.3 mmol/mol, 95% CI -11.5, -1.1) but not in the non-metformin users (-0.17, 95% CI -0.78, 0.43; -1.9 mmol/mol, 95% CI -8.5, 4.7). However, there were no significant differences in the changes in HbA1c (or fasting glucose) between metformin users and non-users in any of the exercise groups compared with control (p> 0.32 for all metformin by group by time interactions). Similarly, metformin did not affect changes in indicators of aerobic fitness, strength and body weight or waist circumference (p ≥ 0.15 for all metformin by group by time interactions). CONCLUSIONS/ INTERPRETATION: Contrary to our hypothesis and to previous short-term studies, metformin did not significantly attenuate the benefits of exercise on glycaemic control or fitness.
RCT Entities:
AIMS/HYPOTHESIS: Some previous studies suggested that metformin might attenuate the effects of exercise on glycaemia or fitness. We therefore examined whether metformin use influenced changes in glycaemic control, fitness, body weight or waist circumference resulting from aerobic and/or resistance training in people with type 2 diabetes participating in an exercise intervention trial. METHODS: After a 4 week run-in period, participants from the Diabetes Aerobic and Resistance Exercise (DARE) trial were randomly assigned to 22 weeks of aerobic training alone, resistance training alone, combined aerobic and resistance exercise training or a waiting-list control group. Of the 251 randomised, 143 participants reported using metformin throughout the entire study period and 82 reported not using metformin at all. RESULTS: Compared with control, aerobic training led to a significant reduction in HbA1c in the metformin users (-0.57%, 95% CI -1.05, -0.10; -6.3 mmol/mol, 95% CI -11.5, -1.1) but not in the non-metformin users (-0.17, 95% CI -0.78, 0.43; -1.9 mmol/mol, 95% CI -8.5, 4.7). However, there were no significant differences in the changes in HbA1c (or fasting glucose) between metformin users and non-users in any of the exercise groups compared with control (p> 0.32 for all metformin by group by time interactions). Similarly, metformin did not affect changes in indicators of aerobic fitness, strength and body weight or waist circumference (p ≥ 0.15 for all metformin by group by time interactions). CONCLUSIONS/ INTERPRETATION: Contrary to our hypothesis and to previous short-term studies, metformin did not significantly attenuate the benefits of exercise on glycaemic control or fitness.
Authors: Daniel Umpierre; Paula A B Ribeiro; Caroline K Kramer; Cristiane B Leitão; Alessandra T N Zucatti; Mirela J Azevedo; Jorge L Gross; Jorge P Ribeiro; Beatriz D Schaan Journal: JAMA Date: 2011-05-04 Impact factor: 56.272
Authors: Joanie Larose; Ronald J Sigal; Normand G Boulé; George A Wells; Denis Prud'homme; Michelle S Fortier; Robert D Reid; Heather Tulloch; Douglas Coyle; Penny Phillips; Alison Jennings; Farah Khandwala; Glen P Kenny Journal: Med Sci Sports Exerc Date: 2010-08 Impact factor: 5.411
Authors: Ronald J Sigal; Glen P Kenny; Normand G Boulé; George A Wells; Denis Prud'homme; Michelle Fortier; Robert D Reid; Heather Tulloch; Douglas Coyle; Penny Phillips; Alison Jennings; James Jaffey Journal: Ann Intern Med Date: 2007-09-18 Impact factor: 25.391
Authors: Barry Braun; Pamela Eze; Brooke R Stephens; Todd A Hagobian; Carrie G Sharoff; Stuart R Chipkin; Benjamin Goldstein Journal: Appl Physiol Nutr Metab Date: 2008-02 Impact factor: 2.665
Authors: Carrie G Sharoff; Todd A Hagobian; Steven K Malin; Stuart R Chipkin; Haiyan Yu; Michael F Hirshman; Laurie J Goodyear; Barry Braun Journal: Am J Physiol Endocrinol Metab Date: 2010-01-13 Impact factor: 4.310
Authors: Normand G Boulé; Cheri Robert; Gordon J Bell; Steven T Johnson; Rhonda C Bell; Richard Z Lewanczuk; Raniah Q Gabr; Dion R Brocks Journal: Diabetes Care Date: 2011-05-20 Impact factor: 19.112
Authors: Andrea M Brennan; Robert A Standley; Steven J Anthony; Kory E Grench; Nicole L Helbling; James P DeLany; Heather H Cornnell; Fanchao Yi; Maja Stefanovic-Racic; Frederico G S Toledo; Paul M Coen; Elvis A Carnero; Bret H Goodpaster Journal: J Gerontol A Biol Sci Med Sci Date: 2022-05-05 Impact factor: 6.591
Authors: Douglas E Long; Kate Kosmac; Cory M Dungan; Marcas M Bamman; Charlotte A Peterson; Philip A Kern Journal: Front Physiol Date: 2022-04-14 Impact factor: 4.755
Authors: Douglas E Long; Bailey D Peck; Steven C Tuggle; Alejandro G Villasante Tezanos; Samuel T Windham; Marcas M Bamman; Philip A Kern; Charlotte A Peterson; Rosicka G Walton Journal: Geroscience Date: 2021-01-18 Impact factor: 7.713
Authors: Barbara Strasser; Lauren M Sparks; Dominik H Pesta; Renata L S Goncalves; Anila K Madiraju Journal: Nutr Metab (Lond) Date: 2017-03-02 Impact factor: 4.169
Authors: Bruno P Moura; Paulo Rs Amorim; Bruno Pp Silva; Sylvia Cc Franceschini; Janice S Reis; João Cb Marins Journal: Diabetol Metab Syndr Date: 2014-02-11 Impact factor: 3.320